The companies also have an expanded three-year software agreement that will increase access for Novartis to Schrödinger’s ...
Schrödinger (NASDAQ:SDGR) shares traded higher on Tuesday despite reporting lower-than-expected Q3 2024 financials after the ...
Schrodinger, Inc. (NASDAQ:SDGR) shares are trading higher on Tuesday. The company disclosed a research collaboration and ...
Physics-based US software specialist Schrödinger’s shares leapt nearly 14% to $22.25 on the back of news that it has entered ...
Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...
Schrödinger today announced a multi-target collaboration and expanded software licensing agreement with Novartis.
Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...
In its recent earnings release for the third quarter of 2024, Schrödinger reported significant developments, including a new collaboration with Novartis, which will see an upfront payment of $150 ...
In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Schrodinger (SDGR – Research Report), with a ...
Die Nachrichten kamen an der Börse gut an; die Aktie beendete den US-Handel mit einem satten Kursplus von 13 Prozent. Laut ...
Die US-Biotechfirma Schrödinger hat eine Forschungskooperation und Lizenzvereinbarung zur Entdeckung neuer Zielmoleküle mit ...
NEW YORK - Schrödinger, Inc. (NASDAQ: SDGR), ein Unternehmen, das sich auf computergestützte molekulare Entdeckungen spezialisiert hat, gab eine bedeutende Kooperations- und Lizenzvereinbarung mit dem ...